Hepatitis B Antiviral Agents

摘要

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:;X-A-Y—Z-L-R1  (I);which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

主权项

1. A compound represented by Formula (I):
X-A-Y—Z-L-R1  (I), or a pharmaceutically acceptable salt thereof, wherein:
X is an optionally substituted aryl or optionally substituted heteroaryl;A is absent, —NHCO— or optionally substituted azolyl;Y is an optionally substituted arylamino or optionally substituted heteroarylamino; wherein the said amino group is directly connected to A, X when A is absent or Z;Z is —S(O)2—, —C(O)—, or —C(O)C(O)—;L is —NR2—, O or —CR1R2—; andR1 and R2 at each occurrence are each independently selected from the group of consisting of hydrogen, optionally substituted —C1-C8 alkyl, optionally substituted —C2-C8 alkenyl, optionally substituted —C2-C8 alkynyl, optionally substituted —C3-C8 cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and alternatively, R1 and R2 are taken together with the atom to which they are attached to form an optionally substituted C3-C8 cycloalkyl or an optionally substituted 3- to 8-membered heterocyclic.